Daptomycin in paediatrics: current knowledge and the need for future research.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2015-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/jac/dku453PMID 25406298
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of daptomycin lock therapy in the treatment of bloodstream infections related to long-term catheter

  2015cited by this paper
• Daptomycin and Its Immunomodulatory Effect: Consequences for Antibiotic Treatment of Methicillin-Resistant Staphylococcus aureus Wound Infections after Heart Surgery

  2014cited by this paper
• Staphylococcus aureus – antimicrobial resistance and the immunocompromised child

  2014cited by this paper
• Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.

  2014cited by this paper
• Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials.

  2014cited by this paper
• Clinical and molecular epidemiology of community-onset invasive Staphylococcus aureus infection in New Zealand children

  2014cited by this paper
• Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012).

  2014cited by this paper
• Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Asia.

  2013cited by this paper
• Pharmacotherapy for pneumococcal infections: an update

  2013cited by this paper
• Microbiology of skin and soft tissue infections in the age of community-acquired methicillin-resistant Staphylococcus aureus.

  2013cited by this paper
• Trends in Invasive Methicillin-Resistant Staphylococcus aureus Infections

  2013cited by this paper
• Hospital‐ and community‐associated methicillin‐resistant Staphylococcus aureus: a 6‐year surveillance study of invasive infections in Chinese children

  2013cited by this paper
• Daptomycin: the role of high-dose and combination therapy for Gram-positive infections.

  2013cited by this paper
• Neonatal Sepsis due to Coagulase-Negative Staphylococci

  2013cited by this paper
• Staphylococcus aureus, including Community-Acquired Methicillin-resistant S. aureus, in a Level III NICU: 2001 to 2008

  2012cited by this paper
• MRSA: the first half century.

  2012cited by this paper
• Successful use of daptomycin in Panton-Valentine leucocidin positive Staphylococcus aureus paediatric osteomyelitis.

  2012cited by this paper
• Pharmacokinetic–pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries

  2012cited by this paper
• Pharmacokinetics and Tolerability of Single-Dose Daptomycin in Young Infants

  2012cited by this paper
• Serum levels of daptomycin in pediatric patients

  2012cited by this paper
• Successful treatment of meticillin-resistant Staphylococcus aureus bacteraemia in a neonate using daptomycin.

  2011cited by this paper
• Outcome of Urinary Tract Infections Caused by Extended Spectrum &bgr;-Lactamase-producing Enterobacteriaceae in Children

  2011cited by this paper
• Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe.

  2010cited by this paper
• Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents.

  2010cited by this paper
• Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.

  2009cited by this paper
• Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline.

  2009cited by this paper
• Daptomycin Use in a Neonate: Serum Level Monitoring and Outcome

  2009cited by this paper
• Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia.

  2009cited by this paper
• Single-Dose Pharmacokinetics of Daptomycin in Children With Suspected or Proved Gram-Positive Infections

  2008cited by this paper
• Daptomycin use in infants: report of two cases with peak and trough drug concentrations

  2008cited by this paper
• Daptomycin Therapy for Invasive Gram-Positive Bacterial Infections in Children

  2007cited by this paper
• Guidelines on Paediatric Dosing on the Basis of Developmental Physiology and Pharmacokinetic Considerations

  2006cited by this paper
• Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

  2006cited by this paper
• Venous Thrombosis Associated With Staphylococcal Osteomyelitis in Children

  2006cited by this paper
• Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection.

  2006cited by this paper
• Pharmacokinetics and Tolerability of Daptomycin at Doses up to 12 Milligrams per Kilogram of Body Weight Once Daily in Healthy Volunteers

  2006cited by this paper
• Enterococcal infection in children.

  2006cited by this paper
• Pharmacokinetics of Daptomycin in a Critically Ill Adolescent with Vancomycin‐Resistant Enterococcal Endocarditis

  2006cited by this paper
• Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.

  2005cited by this paper
• Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection.

  2005cited by this paper
• In Vitro Activity of Daptomycin against Gram-Positive European Clinical Isolates with Defined Resistance Determinants

  2004cited by this paper
• Daptomycin in vitro susceptibility in European Gram-positive clinical isolates.

  2004cited by this paper
• Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.

  2004cited by this paper
• Population Pharmacokinetics of Daptomycin

  2004cited by this paper
• Population Pharmacokinetics of Arbekacin, Vancomycin, and Panipenem in Neonates

  2004cited by this paper
• Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.

  2004cited by this paper
• The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species.

  2003cited by this paper
• Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects

  2003cited by this paper
• Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

  2003cited by this paper
• In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate Staphylococcus aureus and Other Resistant Gram-Positive Pathogens

  2002cited by this paper
• Maturation and growth of renal function: Dosing renally cleared drugs in children

  2000cited by this paper
• Developmental pharmacology.

  1982cited by this paper
• Developmental pharmacology.

  1968cited by this paper

• Intravenous Ceftaroline in Extremely Premature Neonates With Coagulase-Negative Staphylococci Septicemia: A Report of 2 Cases.

  2025cites this paper
• A pharmacovigilance study of daptomycin use in infants under 1 year old based on the FDA adverse event reporting system

  2025cites this paper
• Daptomycin treatment for persistent bacteremia in a pediatric solid organ transplant recipient: case report and literature review.

  2024cites this paper
• Safety and Treatment Outcomes of Infants and Children Treated With Daptomycin: Six-Year Experience From a Pediatric Academic Medical Center

  2024cites this paper
• Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin

  2023cites this paper
• The Role of Coagulase-Negative Staphylococci Biofilms on Late-Onset Sepsis: Current Challenges and Emerging Diagnostics and Therapies

  2023cites this paper
• Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment

  2022cites this paper
• Safety and Efficacy of Daptomycin in Neonates with Coagulase-Negative Staphylococci: Case Series Analysis

  2021cites this paper
• The Use of Daptomycin in the Treatment of Persistent Coagulase-Negative Staphylococcal Sepsis in Premature Infants: A Case Series.

  2021cites this paper
• Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation

  2020cites this paper
• Clinical Pharmacokinetics of Daptomycin

  2020cites this paper
• Bacterial meningitis: new treatment options to reduce the risk of brain damage

  2019cites this paper
• 291 – Pharmacokinetic-Pharmacodynamic Basis of Optimal Antibiotic Therapy

  2018cites this paper
• New Antimicrobial Agents for the Treatment of Staphylococcal Infections in Children.

  2017cites this paper
• Optimizing the Use of Antibacterial Agents in the Neonatal Period

  2016cites this paper
• Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections

  2016cites this paper
• Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents

  2016cites this paper
• Update on the Management of Pediatric Acute Osteomyelitis and Septic Arthritis

  2016cites this paper
• Recovery of a 10-year-old girl from methicillin-resistant Staphylococcus aureus sepsis in response to low-dose ceftaroline treatment

  2016cites this paper
• Vancomycin-resistant Enterococcus bacteremia in a child with acute myeloid leukemia: successful treatment with daptomycin.

  2016cites this paper
• Clinical Effectiveness, Safety Profile, and Pharmacokinetics of Daptomycin in Pediatric Patients: A Systematic Review.

  2016cites this paper
• Daptomycin for Children in Clinical Practice Experience

  2016cites this paper